The effects of omega-3 on blood pressure and the relationship between serum visfatin level and blood pressure in patients with type II diabetes

ARYA Atherosclerosis

Volumn 8, Issue 1, 2012, Pages

  Atar, Mohammad Javad Hosseinzadeh ^a   Hajianfar, Hossein ^a   Bahonar, Ahmad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hypertension; Omega 3; Type 2 Diabetes Mellitus; Visfatin

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BUTTOCK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIP; HUMAN; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84863993872     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-31.
2. Jung CH, Rhee EJ, Kim SY, Shin HS, Kim BJ, Sung KC, et al. Associations between two single nucleotide polymorphisms of adiponectin gene and coronary artery diseases. Endocr J 2006; 53(5): 671-7.
3. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128(2): 389-401.
4. Tribole E. The Ultimate Omega-3 Diet: Maximize the Power of Omega-3s to Supercharge Your Health, Battle Inflammation, and Keep Your Mind Sharp. New York: McGraw-Hill Professional; 2007.
5. Mazlom Z, Ansari H. Effect of anti oxidan Alfa lipoic acid on blood presur in patient with type 2 diabetes. Iranian Journal of Endocrinology and Metabolism 2009; 11(3): 245-50.
6. th ed. New York: McGraw Hill p. 190-192; 1994.
7. Finau SA, Prior IA, Salmond CE. Hypertension among urban and rural Tongans. Med J Aust 1986; 144(1): 16-20.
8. Alwan A. Prevention and control of cardiovascular diseases. Geneva: World Health Organization p. 21; 1995.
9. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91(1): 295-9.
10. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91(4): 1578-81.
11. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307(5708): 426-30.
12. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 2006; 55(10): 2896-902.
13. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88(6): 2399-403.
14. Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ. Modern Nutrition In Health And Disease. Philadelphia: Lippincott Williams & Wilkins p. 1053; 2006.
15. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down regulated by overfeeding in healthy young men. Am J Clin Nutr 2007; 85(2): 399-404.
16. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007; 92(2): 666-72.
17. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76(1): 24-9.
18. Dogru T, Sonmez A, Tasci I, Yilmaz MI, Erdem G, Erturk H, et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007; 21(2): 173-5.
19. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54(10): 2911-6.
20. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006; 110(5): 605-9.
21. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56(4): 565-70.
22. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91(8): 3165-70.
23. Samara A, Pfister M, Marie B, Visvikis-Siest S. Visfatin, low-grade inflammation and body mass index (BMI). Clin Endocrinol (Oxf) 2008; 69(4): 568-74.
24. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999; 34(2): 253-60.
25. Kesavulu MM, Kameswararao B, Apparao C, Kumar EG, Harinarayan CV. Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab 2002; 28(1): 20-6.
26. Malasanos TH, Stacpoole PW. Biological effects of omega-3 fatty acids in diabetes mellitus. Diabetes Care 1991; 14(12): 1160-79
27. Wu LY, Juan CC, Ho LT, Hsu YP, Hwang LS. Effect of green tea supplementation on insulin sensitivity in Sprague-Dawley rats. J Agric Food Chem 2004; 52(3): 643-8.
28. Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, et al. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr 2006; 136(10): 2512-8.
29. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17(4): 223-30.